Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.830 +0.080 (+2.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
ImmunityBio to Present at the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Jim Cramer Advises Buying AZEK, Considers This Stock "Great Long-Term Story"
On CNBC’s "Mad Money Lightning Round,&q... 
Via Benzinga
ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial
ImmunityBio Inc (NASDAQ: IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints ... 
Via Benzinga
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
From ImmunityBio, Inc.
Via Business Wire
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
From ImmunityBio, Inc.
Via Business Wire
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg
Johnson & Johnson (NYSE: JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used in a mass trial of... 
Via Benzinga
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
From ImmunityBio, Inc.
Via Business Wire
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday... 
Via Benzinga
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent
From ImmunityBio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low.... 
Via Benzinga
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
From ImmunityBio, Inc.
Via Business Wire
Cramer Weighs In On Cloudflare, MP Materials And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he should talk more about Cloudflare Inc (NYSE: NET) on the show because it has got a great security component... 
Via Benzinga
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
From ImmunityBio, Inc.
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Atossa Therapeutics (NASDAQ:ATOS)... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP 
Via Benzinga
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients
ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in... 
Via Benzinga
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
From ImmunityBio, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.